MeiraGTx Holdings plc (MGTX) has a MoatMap StockRank of 59/100 based on Quality (32/100), Value (54/100), and Momentum (59/100) factor scores. The current signal is HOLD. MeiraGTx is a clinical-stage gene therapy biotech. It lacks the scale, validated commercial manufacturing capacity, and cash-flow generation of a high-quality CDMO compounder, making it too speculative for our concentrated portfolio.
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing and commercializing novel treatments for inherited diseases, with programs in ophthalmology, salivary gland disorders, and Parkinson's disease. The company differentiates itself with its proprietary gene therapy platforms and a vertically integrated approach, including its own GMP manufacturing facility. This strategic integration supports control over its development pipeline for high-unmet-need indications.
| Price | $9.24 |
| Market Cap | $926M |
| P/E (Forward) | -6.90 |
| Price/Book | -13.45 |
| Return on Invested Capital | -83.7% |
| Gross Margin | 95.4% |
| Operating Margin | -13930.7% |
| Revenue Growth | -84.8% |
| Free Cash Flow | $45M |
MeiraGTx Holdings plc operates in the Biotechnology industry, part of the Healthcare sector (United States).